News & Updates

Reimagining and Reshaping Patient Access for Life Sciences

Discover how emerging electronic benefit verification (eBV) technologies are revolutionizing patient access and support in life sciences organizations. 

This webinar will explore the shift from manual, resource-intensive processes to seamless, automated workflows that enable streamlined verifications for patient access programs driving innovation in copay strategies and direct-to-patient engagement

Join us to learn how automation paired with data-driven approaches is unlocking new opportunities and shaping a more agile, patient-centered future in life sciences

Dermatology is one of the most consumer-influenced and commercially competitive areas in healthcare. More than half of patients rely exclusively on OTC treatments, and a growing share of care occurs outside traditional healthcare settings. For companies developing therapeutics in this space, prescription and claims data provide only a partial view of the full care experience, leaving critical gaps in how disease is experienced, managed, treated, and responded to in the real world.

By connecting directly with individuals over time, a longitudinal, multimodal data approach can more fully characterize dermatologic conditions as they evolve. This includes integrating clinical data with data captured directly from individuals:  imaging, patient-reported symptoms and experience, OTC and prescription use, healthcare utilization, and real-time treatment and condition changes.

This session will explore how this integrated model can sharpen brand positioning, clarify unmet need, and strengthen lifecycle and access strategy in competitive dermatology markets.

Discover why Middlesex County, New Jersey, is a strategic choice for life sciences companies, with strong talent, research depth and site readiness to support innovation, manufacturing and long-term growth.

Enterprise Asset Management (EAM) is critical in GxP environments, yet many life sciences organizations struggle with siloed systems, manual handoffs, and reactive processes that increase downtime and compliance risk. This webinar will demonstrate how autonomous AI agents can improve asset reliability by sensing events in real time, making context-aware decisions, and coordinating actions across EAM, QMS, ERP, and LMS while maintaining human oversight and auditability. 

Using real-world examples like GMP-critical failures, presenters Bill Lucas and Judy Fainor from Blue Mountain show how AI agents can detect issues instantly, open and link deviations, check parts availability, trigger procurement, and enroll staff in training with full traceability. They outline three integration approaches and a maturity model from assistive to selective automation. Key adoption topics include API readiness, security, governance, and human-in-the-loop design. Attendees will learn to shift from reactive to proactive asset strategies, design GxP-ready AI use cases, and apply a phased roadmap that drives value without compromising compliance.

Reducing the time to "First Patient In" remains a challenge, as manual study builds create persistent bottlenecks.

Join Paul O'Donohoe, Senior Director, eCOA Product and Science, Angela May, Senior Consultant, Medidata, and a global pharma expert, as they examine the implementation of next generation eCOA today. This session details how automation, anchored by human expertise, can power fast and high-quality eCOA study builds.

Attendees will learn how to:

• Convert protocols directly into baseline eCOA builds to replace weeks of manual specification.
• Reduce build effort by up to 50% to improve quality and accelerate "First Patient In" dates.
• Leverage smart form recommendations and imports from libraries to remove repetitive build work and safeguard instrument validity.
• Combine AI automation with expert oversight to mitigate regulatory risk and ensure compliance.
• Discover how integrating AI transforms operational efficiency into a competitive advantage, ensuring data quality and a seamless start for your patients.

Join us to discover how operational efficiency builds a more predictable path to First Patient In.

Medical imaging produces essential efficacy and safety evidence across clinical trials; however, fragmentation in image acquisition, quality control, data flow, and analysis introduces substantial bottlenecks to operations and scientific enablement.

Accelerating and improving access, analysis and governance of that data can unblock critical bottlenecks, empowering better decision-making in drug development, where every moment counts.  

Join us for an exploration of how a leading pharmaceutical company has been able to save weeks on data ingestion, accelerate analysis workflows and scale for growth and AI development with a modernized imaging data management platform.  You’ll learn how they are achieving:

• Significant time and resource savings through automated image curation, quality assurance and annotation verification
• Faster, more reliable data access from third parties
• Centralized, scalable workflows for research, advanced analytics, and AI model development
• Improved data governance

The Most Favored Nation (MFN) drug pricing policy represents a rare convergence of political uncertainty, global pricing pressure, and long-term strategic risk for biopharmaceutical companies. While its timing and final form remain uncertain, the range of plausible outcomes is broad and highly consequential—challenging traditional forecasting and linear planning approaches.

This webinar examines MFN through the lens of strategic scenario planning. Drawing on established foresight methodologies adapted for biopharma, the session explores how organizations can systematically assess MFN-driven futures, integrate macroeconomic and policy uncertainty, and develop strategic options that remain viable across divergent scenarios. Topics include navigating alternative MFN futures, selecting the appropriate scenario planning approach, anticipating stakeholder responses to uncertain trends, and using early warning signposts to guide decision-making as policy conditions evolve.

Cell therapy developers are under pressure to accelerate safety testing without compromising quality or regulatory compliance. Download today to learn how PCR-based mycoplasma and sterility testing can replace slow culture methods, delivering faster, more flexible, and more reliable results.